bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2019-64-2-188-197bloodjour-138Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREКОМБИНИРОВАННАЯ ТЕРАПИЯ ПРИ МИЕЛОФИБРОЗЕCOMBINATION THERAPY FOR MYELOFIBROSIShttps://orcid.org/0000-0001-7757-318XГрибковаИ. В.GribkovaI. V.

Грибкова Ирина Владимировна, кандидат биологических наук, ведущий научный сотрудник научно-клинического отдела 

тел.: +7(499)144-00-30; 121096, г. Москва, ул. Минская, д. 12, корп. 2. 

Irina V. Gribkova, Cand. Sci. (Biol.), Leading Researcher, Scientific and Clinical Department

tel.: +7(499)144-00-30; 121096, Moscow, Minskaya str., 12, building 2.

igribkova@yandex.ruОлейникЮ. А.OleinikYu. A.

Олейник Юлия Андреевна, врач-гематолог

Julia A. Oleynik, Hematologist

ШалаевС. А.ShalaevS. A.

Шалаев Сергей Александрович, врач-гематолог

Sergey A. Shalaev, Hematologist

ДавыдовскаяМ. В.DavydovskayaM. V.

Давыдовская Мария Вафаевна, доктор медицинских наук, заместитель директора по научной работе 

профессор кафедры неврологии, нейрохирургии и медицинской генетики

тел.: +7(499)144-00-30.

Maria V. Davydovskaya, Dr. Sci. (Med.), Deputy Director for Research 

Prof., Department of Neurology, Neurosurgery and Medical Genetics

tel.: +7(499)144-00-30.

mdavydovskaya@gmail.comКокушкинК. А.KokushkinK. A.

Кокушкин Константин Александрович, директор 

тел.: +7(499)144-00-30; 121096, г. Москва, ул. Минская, д. 12, корп. 2.

Konstantin A. Kokushkin, Director

kokushkinka@gmail.comГБУ «Научно-практический центр клинических исследований и оценки медицинских технологий» Департамента здравоохранения г. МосквыРоссияScientific Practical Centre for Clinical Research and Assessment of Medical TechnologiesRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Министерства здравоохранения Российской ФедерацииРоссияN.N. Petrov National Medical Research Centre for OncologyRussian FederationГБУ «Научно-практический центр клинических исследований и оценки медицинских технологий» Департамента здравоохранения г. Москвы; ФБОУ «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияScientific Practical Centre for Clinical Research and Assessment of Medical Technologies; Pirogov Medical UniversityRussian Federation201904102019642188197Copyright © Грибкова И.В., Олейник Ю.А., Шалаев С.А., Давыдовская М.В., Кокушкин К.А., 20192019Грибкова И.В., Олейник Ю.А., Шалаев С.А., Давыдовская М.В., Кокушкин К.А.Gribkova I.V., Oleinik Y.A., Shalaev S.A., Davydovskaya M.V., Kokushkin K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/138Введение

Введение. Руксолитиниб — препарат для патогенетического лечения миелофиброза (МФ). В настоящее время разработаны новые препараты для лечения МФ. Поиск оптимальных комбинаций этих препаратов с руксолитинибом представляется логичным подходом к разработке терапии МФ.

Цель настоящего обзора

Цель настоящего обзора: систематизация данных о применении руксолитиниба у больных МФ в комбинациях с препаратами, которые одобрены или в настоящее время находятся на стадии исследования для лечения МФ.

Основные сведения

Основные сведения. В обзор вошли данные статей, найденные в базах данных PubMed и Elibrary.ru, включая клинические случаи, оригинальные научные исследования и обзоры. Обсуждаются предварительные результаты клинических исследований различных рациональных комбинаций, которые могут улучшать формы болезни, не поддающиеся лечению при монотерапии руксолитинибом, например такие, как фиброз костного мозга и анемия. Наиболее обнадеживающие результаты получены при комбинациях азацитидина с руксолитинибом, панобиностата с руксолитинибом, интерферона α с руксолитинибом.

Introduction

Introduction. Ruxolitinib presents itself as a drug for the pathogenetic treatment of myelofibrosis (MF). New drugs have recently been developed for the treatment of MF. A search for optimal combinations of these drugs with ruxolitinib appears to be a logical approach to the development of MF therapy.

Aim

Aim. To summarize data on the use of ruxolitinib in combination with various drugs approved or currently being studied in terms of their applicability for MF treatment.

General findings

General findings. The review analyses data in publications retrieved from the PubMed and Elibrary.ru databases, including clinical cases, original research papers and reviews. We discuss preliminary results of clinical trials of various rational combination therapies, which have demonstrated a high efficacy for the forms of the disease untreatable with ruxolithinib monotherapy, e.g. bone marrow fibrosis and anemia. Combinations of ruxolithinib with azacytidine, panobinostat and α-interferon have shown the most promising results.

миелофиброзруксолитинибкомбинированная терапияmyelofibrosisruxolitinibcombination therapyReferencesVerstovsek S., Mesa R.A., Gotlib J., et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New Eng J Med. 2012; 366: 799–807.Verstovsek S., Mesa R.A., Gotlib J., et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New Eng J Med. 2012; 366: 799–807.Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New Eng J Med. 2012; 366: 787–98.Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New Eng J Med. 2012; 366: 787–98.Plosker G.L. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015; 75: 297–308. DOI: 10.1007/s40265-015-0351-8Plosker G.L. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015; 75: 297–308. DOI: 10.1007/s40265-015-0351-8Cervantes F., Vannucchi A.M., Kiladjian J.J., et al. COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047–53.Cervantes F., Vannucchi A.M., Kiladjian J.J., et al. COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047–53.Harrison C.N., Vannucchi A.M., Kiladjian J.J., et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–7.Harrison C.N., Vannucchi A.M., Kiladjian J.J., et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–7.Bose P., Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017; 130(2): 115–25. DOI: 10.1182/blood-2017-04-742288Bose P., Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017; 130(2): 115–25. DOI: 10.1182/blood-2017-04-742288Vannucchi A.M., Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica. 2011; 96: 1398–402.Vannucchi A.M., Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica. 2011; 96: 1398–402.Gowin K., Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013; 22: 1603–11.Gowin K., Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013; 22: 1603–11.Assi R., Verstovsek S., Daver N. ‘JAK-ing’ up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol. 2017; 24(2): 115–24. DOI: 10.1097/MOH.0000000000000320Assi R., Verstovsek S., Daver N. ‘JAK-ing’ up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol. 2017; 24(2): 115–24. DOI: 10.1097/MOH.0000000000000320DeAngelo D.J., Mesa R.A., Fiskus W., et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, postessential thrombocythaemia, and postpolycythaemia vera myelofibrosis. Br J Haematol. 2013; 162: 326–35.DeAngelo D.J., Mesa R.A., Fiskus W., et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, postessential thrombocythaemia, and postpolycythaemia vera myelofibrosis. Br J Haematol. 2013; 162: 326–35.Baffert F., Evrot E., Ebel N., et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2 V617F-driven disease. Blood. 2011; 118: 798.Baffert F., Evrot E., Ebel N., et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2 V617F-driven disease. Blood. 2011; 118: 798.Harrison C.N., Kiladjian J.J., Heidel F.H., et al. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF). Blood. 2015; 126: 4060Harrison C.N., Kiladjian J.J., Heidel F.H., et al. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF). Blood. 2015; 126: 4060Jovanovic J.V., Ivey A., Vannucchi A.M., et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F- associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27: 2032.Jovanovic J.V., Ivey A., Vannucchi A.M., et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F- associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27: 2032.Daver N., Cortes J.E., Pemmaraju N., et al. Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF). Blood. 2016; 128: 1127.Daver N., Cortes J.E., Pemmaraju N., et al. Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF). Blood. 2016; 128: 1127.Tefferi A., Cervantes F., Mesa R., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8): 1395–8. DOI: 10.1182/blood-2013-03-488098Tefferi A., Cervantes F., Mesa R., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8): 1395–8. DOI: 10.1182/blood-2013-03-488098Barosi G., Bordessoule D., Briere J., et al. European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005; 106(8): 2849–53.Barosi G., Bordessoule D., Briere J., et al. European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005; 106(8): 2849–53.Rampal R., Mascarenhas J., Kosiorek H.E., et al. Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and Post-MPN AML: results of a phase I study (myeloproliferative disorders research consortium 109 trial). Blood. 2016; 128: 1124.Rampal R., Mascarenhas J., Kosiorek H.E., et al. Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and Post-MPN AML: results of a phase I study (myeloproliferative disorders research consortium 109 trial). Blood. 2016; 128: 1124.Bose P., Verstovsek S., Gasior Y., et al. Phase I/II study of ruxolitinib (RUX) with decitabine (DAC) in patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): phase I results. Presented at the 58th Annual Meeting of the American Society of Hematology. 2016; 4262.Bose P., Verstovsek S., Gasior Y., et al. Phase I/II study of ruxolitinib (RUX) with decitabine (DAC) in patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): phase I results. Presented at the 58th Annual Meeting of the American Society of Hematology. 2016; 4262.Меликян А.Л., Суборцева И.Н. Классические Ph-негативные ми ело пролиферативные неоплазии. Клиническая онкогематология. 2015; 8(2): 201–32.Melikyan A.L., Subortseva I.N. Classic Ph-negative myeloproliferative neoplasia. Klinicheskaya onkogematologiya. 2015; 8(2): 201–32 (In Russian).Gupta V., Harrison C.N., Hasselbalch H., et al. Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood. 2015; 126: 825.Gupta V., Harrison C.N., Hasselbalch H., et al. Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood. 2015; 126: 825.Durrant S., Nagler A., Vannucchi A.M., et al. An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. Blood. 2015; 126(23): 827.Durrant S., Nagler A., Vannucchi A.M., et al. An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. Blood. 2015; 126(23): 827.Moyo T.K., Sochacki A., Ayers G.D., et al. Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis. Blood. 2016; 128: 1125.Moyo T.K., Sochacki A., Ayers G.D., et al. Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis. Blood. 2016; 128: 1125.Verstovsek S., Mesa R., Foltz L.M., et al. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014; 124: 713.Verstovsek S., Mesa R., Foltz L.M., et al. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014; 124: 713.Verstovsek S., Mesa R.A., Foltz L.M., et al. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood. 2015; 126: 56.Verstovsek S., Mesa R.A., Foltz L.M., et al. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood. 2015; 126: 56.Меликян А.Л., Суборцева И.Н. Миелопролиферативные новообразования: новые данные. Клиническая онкогематология. 2016; 9 (2): 218–28.Melikyan A.L., Subortseva I.N. Myeloproliferative neoplasia: new data. Klinicheskaya onkogematologiya. 2016; 9(2): 218–28 (In Russian).Mikkelsen S.U., Kjaer L., Skov V., et al. Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial — an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. Blood. 2015; 126(23): 824.Mikkelsen S.U., Kjaer L., Skov V. et al. Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial — an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. Blood. 2015;126(23):824.Mikkelsen S.U., Kjaer L., Bjørn M.E., et al. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med. 2018; 7(8): 3571–81. DOI: 10.1002/cam4.1619Mikkelsen S.U., Kjaer L., Bjørn M.E. et al. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med. 2018;7(8):3571–81. DOI: 10.1002/cam4.1619Stahl M., Zeidan A.M. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017; 10(5): 459–77. DOI: 10.1080/17474086.2017.1317590Stahl M., Zeidan A.M. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017;10(5):459–77. DOI: 10.1080/17474086.2017.1317590Gowin K., Kosiorek H., Dueck A., et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res. 2017; 60: 31–5. DOI: 10.1016/j.leukres.2017.06.005Gowin K., Kosiorek H., Dueck A., et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res. 2017; 60: 31–5. DOI: 10.1016/j.leukres.2017.06.005Stegelmann F., Bangerter M., Heidel F.H., et al. A phase-Ib/II study of ruxolitinib plus pomalidomide in myelofibrosis. Blood. 2015; 126(23): 826.Stegelmann F., Bangerter M., Heidel F.H., et al. A phase-Ib/II study of ruxolitinib plus pomalidomide in myelofibrosis. Blood. 2015; 126(23): 826.Daver N., Cortes J., Newberry K., et al. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015; 100: 1058–63.Daver N., Cortes J., Newberry K., et al. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015; 100: 1058–63.Rampal R., Pinzon-Ortiz M., Varshini H.A.S., et al. Synergistic Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Blood. 2016; 128(22): 634.Rampal R., Pinzon-Ortiz M., Varshini H.A.S., et al. Synergistic Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Blood. 2016; 128(22): 634.Kuykendall A.T., Talati C., Al Ali N., et al. The treatment landscape of myelofibrosis before and after ruxolitinib approval. Clin Lymphoma Myeloma Leuk. 2017; 17: 45–53.Kuykendall A.T., Talati C., Al Ali N., et al. The treatment landscape of myelofibrosis before and after ruxolitinib approval. Clin Lymphoma Myeloma Leuk. 2017; 17: 45–53.Caocci G., Ghiani S., Mocci C., La Nasa G. Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. Acta Haematol. 2018; 139 (3): 164–5. DOI: 10.1159/000487582Caocci G., Ghiani S., Mocci C., La Nasa G. Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. Acta Haematol. 2018; 139(3): 164–5. DOI: 10.1159/000487582Фоминых М.С., Шуваев В.А., Мартынкевич И.С. и др. Комбинированный режим терапии руксолитинибом и малыми дозами цитозара или меркаптопурина у пациентов с бластным кризом миелофиброза. Онкогематология. 2016; 11(2): 37–9. DOI: 10.17650/1818-8346-2016-11-2-37-39Fominykh M.S., Shuvaev V.A., Martynkevich I.S., et al. Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blastphase myelofibrosis]. Oncohematologiay. 2016; 11(2): 37–9 (In Russian). DOI: 10.17650/1818-8346-2016-11-2-37-39

The authors declare that there are no conflicts of interest present.